Key facts
- Notable investors include The Cambria Group, Pacific Lake, Endurance Search Partners, Accel-KKR, BK Growth — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NovoPath
- ·The full record, as it builds
Funding rounds
No funding rounds for NovoPath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovoPath
Developer of an anatomic pathology laboratory information system (APLIS) software intended for pathology labs. The company's software helps in workflow management and to record, manage, and store data, helping clients to add ancillary molecular tests to their workflows within a single case, in turn automatically producing a single report.
- Sector
- Healthcare
- HQ
- Bridgewater, NJ, United States
- Founded
- 1993
- Employees
- 47
- Website
- novopath.com/
- Ownership
- Privately Held (backing)
NovoPath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovoPath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovoPath in its N-PORT filings yet. We sweep new filings monthly.